Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...

(Reuters) -German drugmaker CureVac and GSK reached an agreement with BioNTech and Pfizer on Thursday to resolve a years-long ...

CureVac (CVAC) and GSK (GSK) to receive $740M and other payments in a settlement with Pfizer (PFE) and BioNTech (BNTX) over ...

Pfizer delivered a strong Q2 earnings beat, raising FY2025 guidance and demonstrating effective cost-cutting. Learn why PFE ...

Pfizer said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting ...

Investor sentiment has been adversely affected by worries regarding the company’s drug pipeline. Nonetheless, we believe PFE ...

And better still, healthy and growing dividend-paying stocks tend to increase their payouts over time. Pfizer's total annual ...

Contract Development and Manufacturing Organizations (CDMOs) have carved out a lucrative niche within the biopharma industry, ...

Pfizer Inc. (NYSE: PFE) is one of the Most Undervalued Long Term Stocks to Buy According to Hedge Funds. On August 5, the ...

Pfizer CEO Albert Bourla is expected at a pro-Trump fundraiser on Friday, sources told CBS News, one day after the president ...

Chief Executive Albert Bourla says he is hopeful about finding a solution in response to Trump’s demand for price cuts.

The complicated legal wrangling has been brought to a close after CureVac and BioNTech settled their mRNA patent litigation ...